|1.||MacDonald, Patricia A: 10 articles (11/2013 - 03/2005)|
|2.||Hosoya, Tatsuo: 9 articles (09/2015 - 06/2011)|
|3.||Becker, Michael A: 8 articles (02/2012 - 03/2005)|
|4.||Schumacher, H Ralph: 8 articles (02/2010 - 03/2005)|
|5.||Yamamoto, Tetsuya: 7 articles (09/2015 - 06/2011)|
|6.||Ueda, Takanori: 7 articles (09/2015 - 06/2011)|
|7.||Hunt, Barbara: 7 articles (07/2012 - 11/2008)|
|8.||Zhao, Lin: 7 articles (01/2011 - 03/2005)|
|9.||Shiozawa, Aki: 6 articles (12/2015 - 03/2014)|
|10.||Fujimori, Shin: 6 articles (09/2015 - 06/2011)|
03/01/2015 - "In open-label extension studies, 3-5 years' treatment with febuxostat maintained a target sUA level of <6.0 mg/dL in most patients; sustained reduction in sUA level was associated with near elimination of gout flares and improved tophus status. "
11/01/2013 - "Febuxostat, initially introduced in the United States in 2009, was the first new treatment option for gout in over 40 years. "
05/01/2009 - "Febuxostat: a new treatment for hyperuricaemia in gout."
11/01/2013 - "Utilization management strategies likely result in gaps in gout treatment; 35% of patients with a denied febuxostat claim in this study population did not fill a prescription for any chronic gout therapy within a month of the claim denial. "
01/01/2013 - "Preservation of renal function during gout treatment with febuxostat: a quantitative study."
09/14/1993 - "These results suggest that TEI-6720 may be useful for the treatment of hyperuricemia."
12/01/2015 - "Efficacy of Febuxostat for Slowing the GFR Decline in Patients With CKD and Asymptomatic Hyperuricemia: A 6-Month, Double-Blind, Randomized, Placebo-Controlled Trial."
01/01/2014 - "In the current study, we investigated the effects of oral febuxostat in patients with advanced CKD with asymptomatic hyperuricemia. "
01/01/2014 - "In this preliminary report, we present 12-16 week results from a multicenter, general practice study in which we evaluated the usefulness of febuxostat in a cohort of untreated patients with hyperuricemia with a high prevalence of CVD. "
09/01/2015 - "We assessed the efficacy and adverse effects of febuxostat in male hyperuricemia patients. "
|3.||Renal Insufficiency (Renal Failure)
06/01/2010 - "Dosage adjustment in mild-to-moderate renal insufficiency is unnecessary; however, data are lacking on the safety of febuxostat in patients with severe renal impairment. "
07/01/2014 - "If the urate target cannot be achieved, the therapy should be switched to febuxostat, which is appropriate with mild-to-moderate renal failure. "
04/01/2008 - "The dosage reduction of the new XDH inhibitors, febuxostat and FYX-051, is not necessary in patients with renal insufficiency because renal excretion is not main excretory pathway. "
06/01/2015 - "Available are the xanthine oxidase inhibitors, allopurinol and febuxostat; the latter is better suited for patients with moderate renal insufficiency. "
11/01/2009 - "The new xanthine oxidase inhibitor febuxostat constitutes a novel option for patients with renal insufficiency or intolerance to allopurinol."
|4.||Hematologic Neoplasms (Hematological Malignancy)
01/01/2014 - "Records of adult patients with newly diagnosed or relapsed hematologic malignancies who received febuxostat within 7 days before initiation of chemotherapy were retrieved retrospectively at a single institute. "
10/01/2015 - "Patients with hematologic malignancies at intermediate to high TLS risk grade were randomized to receive febuxostat or allopurinol, starting 2 days before induction chemotherapy, for 7-9 days. "
10/01/2015 - "FLORENCE: a randomized, double-blind, phase III pivotal study of febuxostat versus allopurinol for the prevention of tumor lysis syndrome (TLS) in patients with hematologic malignancies at intermediate to high TLS risk."
12/01/2014 - "Febuxostat for management of tumor lysis syndrome including its effects on levels of purine metabolites in patients with hematological malignancies - a single institution's, pharmacokinetic and pilot prospective study."
12/01/2014 - "In this single-institution, short-term and pilot prospective study, the efficacy of a new xanthine oxidase inhibitor, febuxostat, as an alternative to conventional allopurinol, including its effects on hypoxanthine and xanthine, was evaluated in 10 consecutive patients with hematological malignancies at intermediate risk for TLS. "
10/19/2012 - "Febuxostat suppressed renal ischemia-reperfusion injury via reduced oxidative stress."
01/01/2015 - "Febuxostat pretreatment attenuates myocardial ischemia/reperfusion injury via mitochondrial apoptosis."
03/01/2013 - "The present study was undertaken to demonstrate whether febuxostat is superior to allopurinol in prevention of the local and remote harmful effects of small intestinal ischemia/reperfusion injury in rats. "
|2.||Uric Acid (Urate)
|6.||benzbromarone drug combination allopurinol
|1.||Renal Dialysis (Hemodialysis)
|2.||Transplantation (Transplant Recipients)
|4.||Drug Therapy (Chemotherapy)
|5.||Investigational Therapies (Experimental Therapy)